These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus. Garg SK; Anderson JH; Perry SV; Mackenzie T; Keith P; Jennings MK; Hansen MM; Chase HP Diabet Med; 1999 May; 16(5):384-7. PubMed ID: 10342337 [TBL] [Abstract][Full Text] [Related]
43. Insulin analogues and management of diabetes mellitus. Vaidyanathan B; Menon PS Indian J Pediatr; 2000 Jun; 67(6):435-41. PubMed ID: 10932964 [TBL] [Abstract][Full Text] [Related]
44. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Roper NA; Bilous RW Diabet Med; 1998 Dec; 15(12):1063-4. PubMed ID: 9868982 [TBL] [Abstract][Full Text] [Related]
45. The use of lispro for high sugar content snacks between meals in intensive insulin regimens. Kong N; Kitchen MM; Ryder RE Diabet Med; 2000 Apr; 17(4):331-2. PubMed ID: 10821304 [No Abstract] [Full Text] [Related]
46. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683 [No Abstract] [Full Text] [Related]
48. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Lindström T; Hedman CA; Arnqvist HJ Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113 [TBL] [Abstract][Full Text] [Related]
49. Insulin analogues: new agents for improving glycemic control. White JR; Campbell RK; Hirsch I Postgrad Med; 1997 Feb; 101(2):58-60, 63-5, 70. PubMed ID: 9046926 [TBL] [Abstract][Full Text] [Related]
50. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Roach P; Woodworth JR Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642 [TBL] [Abstract][Full Text] [Related]
51. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428 [TBL] [Abstract][Full Text] [Related]
52. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Ahmed AB; Home PD Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735 [TBL] [Abstract][Full Text] [Related]
53. Insulin lispro: its role in the treatment of diabetes mellitus. Campbell RK; Campbell LK; White JR Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409 [TBL] [Abstract][Full Text] [Related]
54. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Yamada S; Watanabe M; Kitaoka A; Shiono K; Atsuda K; Tsukamoto Y; Kawana Y; Irie J Intern Med; 2007; 46(18):1513-7. PubMed ID: 17878636 [TBL] [Abstract][Full Text] [Related]
56. Lispro insulin is suitable for external pumps but not for implantable pumps. Demirdjian S; Bardin C; Savin S; Zirinis P; Chast F; Slama G; Sélam JL Diabetes Care; 1998 May; 21(5):867-8. PubMed ID: 9589258 [No Abstract] [Full Text] [Related]
57. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. Herz M; Arora V; Campaigne BN; Scholtz HE; Potgieter MA; Mollentze W S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948 [TBL] [Abstract][Full Text] [Related]
59. Cannula occlusion with use of insulin lispro and insulin infusion system. Wright AW; Little JA Diabetes Care; 1998 May; 21(5):874-5. PubMed ID: 9589263 [No Abstract] [Full Text] [Related]